Nakajima, Akihiro
Yanagimura, Fumihiro
Saji, Etsuji
Shimizu, Hiroshi
Toyoshima, Yasuko
Yanagawa, Kaori
Arakawa, Musashi
Hokari, Mariko
Yokoseki, Akiko
Wakasugi, Takahiro
Okamoto, Kouichirou
Takebayashi, Hirohide
Fujii, Chihiro
Itoh, Kyoko
Takei, Yo-ichi
Ohara, Shinji
Yamada, Mitsunori
Takahashi, Hitoshi
Nishizawa, Masatoyo
Igarashi, Hironaka
Kakita, Akiyoshi
Onodera, Osamu
Kawachi, Izumi http://orcid.org/0000-0002-7140-8500
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP20K07899, JP23K06923, JP21K07412)
MHLW Research Program on Rare and Intractable Diseases (JPMH 20FC1030, JPMH 23FC1009)
Article History
Received: 13 February 2024
Revised: 21 March 2024
Accepted: 25 March 2024
First Online: 24 April 2024
Declarations
:
: AN, FY, ES, HS, YT, KY, MA, MH, AY, TW, KO, H.Takebayashi, CF, KI, YT, SO, MY, H. Takahashi, MN, HI, AK, and OO have no competing interests to disclose. IK reports receiving funding for research, travel, and/or speaker’s honoraria from Chugai Pharmaceuticals, Novartis Pharma, Biogen, Alexion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Teijin Pharma, Argenx, and Daiichi-Sankyo and is a scientific advisory board member for Mitsubishi Tanabe Pharma and Chugai Pharmaceuticals.